ARGX
682.926 EUR
-0.07%
Today
+1.07%
1D
Market is closed
Sun
Closed
Mon
10:01 AM ~ 6:30 PM
Tue
10:01 AM ~ 6:30 PM
Wed
10:01 AM ~ 6:30 PM
Thu
10:01 AM ~ 6:30 PM
Fri
10:01 AM ~ 6:30 PM
Sat
Closed
Information
Name
Argenx Leveraged ( BE )
Currency
EUR
Standard Leverage
1X
Enhanced Leverage
3X
Overnight Fees Buy
-0.0137%
Overnight Fees Sell
-0.0030%
Market Cap
42.41B
Avg Daily Volume
112.49K
52 Week High
810 EUR
52 Week Low
456.6 EUR
Trading Hours
See hours
Overnight Fees Calculator
| Daily Overnight Fee % | Daily Overnight Fee $ | |
|---|---|---|
| BUYS | -0.01370% | $(0.137) |
| SELLS | -0.00300% | $(0.030) |
*Results displayed are estimates. Actual fees may differ from those shown as market conditions change.
Business Summary
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Top News
Argenx
+1.07%
Here’s Why argenx SE (ARGX) Rose in Q3
finance.yahoo.com
4mo ago
Argenx
+1.07%
argenx SE (ARGX) Rose due to Increased Sales of its Vyvgart Medication
finance.yahoo.com
5mo ago
Argenx
+1.07%
Should You Be Confident in Argenx SE’ (ARGX) Long-Term Profit Cycle?
finance.yahoo.com
5mo ago
Show more
Frequently Asked Questions
What are healthcare stocks and why are they important to investors?
Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.
Are healthcare stocks less volatile?
Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.
What drives growth in healthcare investments?
Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.
What are the risks of investing in healthcare?
Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.
